Total Payments
$1.5M
2024 Payments
$66,000
Companies
19
Transactions
395
Payment Breakdown by Category
Research$1.1M (74.6%)
Consulting$364,860 (24.5%)
Other$12,000 (0.8%)
Travel$548.84 (0.0%)
Food & Beverage$321.85 (0.0%)
Gifts$15.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 259 | 74.6% |
| Consulting Fee | $364,860 | 120 | 24.5% |
| Honoraria | $12,000 | 5 | 0.8% |
| Travel and Lodging | $548.84 | 4 | 0.0% |
| Food and Beverage | $321.85 | 6 | 0.0% |
| Gift | $15.00 | 1 | 0.0% |
Payments by Type
Research
$1.1M
259 transactions
General
$377,746
136 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $376,670 | 16 | $0 (2021) |
| Roche Products Limited | $225,040 | 48 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $214,020 | 74 | $0 (2021) |
| ABBVIE INC. | $174,750 | 81 | $0 (2024) |
| Hoffmann-La Roche Limited | $143,000 | 27 | $0 (2020) |
| AstraZeneca UK Limited | $98,780 | 24 | $0 (2024) |
| Dr.Reddy's Laboratories,Inc. | $66,965 | 43 | $0 (2023) |
| Janssen Research & Development, LLC | $38,435 | 16 | $0 (2021) |
| EMD Serono, Inc. | $38,320 | 15 | $0 (2021) |
| Genentech, Inc. | $28,360 | 13 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $66,000 | 24 | AstraZeneca UK Limited ($35,420) |
| 2023 | $109,970 | 25 | AstraZeneca UK Limited ($61,760) |
| 2022 | $94,625 | 29 | Roche Products Limited ($61,935) |
| 2021 | $139,360 | 51 | Roche Products Limited ($86,885) |
| 2020 | $97,185 | 55 | Merck Sharp & Dohme Corporation ($33,665) |
| 2019 | $253,848 | 71 | Hoffmann-La Roche Limited ($86,365) |
| 2018 | $341,780 | 65 | E.R. Squibb & Sons, L.L.C. ($146,015) |
| 2017 | $384,032 | 75 | E.R. Squibb & Sons, L.L.C. ($147,655) |
All Payment Transactions
395 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,220.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $4,600.00 | General |
| Category: Oncology | ||||||
| 09/10/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $360.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 08/06/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,080.00 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $1,860.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 08/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,110.00 | Research |
| Study: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 07/02/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $5,400.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 07/02/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $5,020.00 | General |
| Category: Oncology | ||||||
| 06/04/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 05/07/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $3,580.00 | General |
| Category: Oncology | ||||||
| 05/07/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $2,820.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 05/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,110.00 | Research |
| Study: A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 04/06/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $4,380.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 04/02/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $7,740.00 | General |
| Category: Oncology | ||||||
| 04/02/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $4,020.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 03/19/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $1,600.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 03/12/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $6,180.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 03/12/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,160.00 | General |
| Category: Oncology | ||||||
| 02/06/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,420.00 | General |
| Category: Oncology | ||||||
| 02/06/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $1,320.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 01/09/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $3,940.00 | General |
| Category: Oncology | ||||||
| 01/09/2024 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $420.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 12/05/2023 | Roche Products Limited | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $3,600.00 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M12-914 | AbbVie, Inc. | $138,260 | 37 |
| A Randomized Multi center Phase III Study of Nivolumab Versus Sorafenib as First Line Treatment in Patients With Advanced Hepatocellular Carcinoma CheckMate 459 CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459 | E.R. Squibb & Sons, L.L.C. | $118,205 | 3 |
| A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | Hoffmann-La Roche Limited | $105,120 | 18 |
| Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence | Roche Products Limited | $74,320 | 22 |
| PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | Roche Products Limited | $70,600 | 13 |
| A Phase 1 2 Dose escalation Open label Non comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis and a Randomized Open label Study of Nivolumab vs S | E.R. Squibb & Sons, L.L.C. | $67,910 | 1 |
| A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma | Dr.Reddy's Laboratories,Inc. | $65,005 | 35 |
| TECENTRIQ PLUS AVASTIN FOLLOWING CURATIVE RESECTION IN PATIENTS AT HIGH RISK OF RECURRENCE | Roche Products Limited | $56,060 | 10 |
| A Randomized Multi center Phase III Study of Nivolumab versus Sorafenib as First LineTreatment in P | E.R. Squibb & Sons, L.L.C. | $46,320 | 1 |
| PHASE 3 R R CLL WITH GDC0199 BR | Hoffmann-La Roche Limited | $37,880 | 9 |
| A Phase 1 2 Dose escalation Open label Non comparative Study of Nivolumab or Nivolumab | E.R. Squibb & Sons, L.L.C. | $34,620 | 1 |
| EMR 200647-001 | EMD Serono, Inc. | $30,280 | 11 |
| ATEZOLIZUMAB P1B COMBO ATEZO AND ANTIVEGF THERAPIES WITH SOLID TUMORS | Genentech, Inc. | $28,360 | 13 |
| A Phase 1 2 Dose escalation Open label Non comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis and a Randomized Open label Study of Nivolumab | E.R. Squibb & Sons, L.L.C. | $26,615 | 1 |
| PCYC-1112-CA | Pharmacyclics LLC, An AbbVie Company | $24,955 | 4 |
| A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR A | Roche Products Limited | $24,060 | 3 |
| A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma CheckMate 459 CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459 | E.R. Squibb & Sons, L.L.C. | $22,780 | 2 |
| A Phase 12, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis and a Randomized, Open-label Study of Nivolumab | E.R. Squibb & Sons, L.L.C. | $21,675 | 1 |
| A PHASE III OPEN LABEL RANDOMIZED MULTICENTER TRIAL OF OFATUMUMAB MAINTENANCE TREATMENT VERSUS NO FURTHER TREATMENT IN SUBJECTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA CLL WHO HAVE RESPONDED TO INDUCTION THERAPY | NOVARTIS PHARMACEUTICALS CORPORATION | $19,250 | 2 |
| A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Adv | E.R. Squibb & Sons, L.L.C. | $15,795 | 2 |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | Janssen Research & Development, LLC | $10,125 | 6 |
| A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459) | E.R. Squibb & Sons, L.L.C. | $9,085 | 2 |
| A Phase 12, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects Who Are Naive to Systemic Therapy | E.R. Squibb & Sons, L.L.C. | $8,805 | 1 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemiax2FSmall Lymphocytic Lymphoma | ABBVIE INC. | $6,570 | 4 |
| A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | EMD Serono, Inc. | $6,440 | 3 |
| M12-895 | AbbVie, Inc. | $6,420 | 15 |
| A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects Who Are Naive to Systemic Therapy | E.R. Squibb & Sons, L.L.C. | $4,860 | 1 |
| M13-365 | AbbVie, Inc. | $4,285 | 2 |
| M14-728 | AbbVie, Inc. | $4,125 | 5 |
| M12-175 | AbbVie, Inc. | $3,645 | 2 |
| M12-914 | AbbVie Inc. | $3,260 | 6 |
| M14-728 | AbbVie Inc. | $3,250 | 2 |
| A Study of PCI32765 Ibrutinib in Combination With Either Bendamustine and Rituximab or Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Participants With Previously Treated Indolent Non Hodgkin Lymphoma | Janssen Research & Development, LLC | $1,620 | 4 |
| A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Conconcurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer | EMD Serono, Inc. | $1,600 | 1 |
| A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar DRLRI With MabThera in Subjects With Previously Untreated CD20-Positive LTB Follicular Lymphoma | Dr.Reddy's Laboratories,Inc. | $1,560 | 5 |
| M13-982 | AbbVie, Inc. | $1,320 | 1 |
| A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ABBVIE INC. | $1,110 | 1 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma | ABBVIE INC. | $1,110 | 1 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ABBVIE INC. | $735.00 | 2 |
| Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in LTB Follicular Lymphoma (FLINTER) | Dr.Reddy's Laboratories,Inc. | $400.00 | 3 |
| M12-895 | AbbVie Inc. | $370.00 | 1 |
| Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women | ABBVIE INC. | $160.00 | 1 |
| A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ABBVIE INC. | $130.00 | 1 |
About Max Rosen, MD MPH
Max Rosen, MD MPH is a Diagnostic Radiology healthcare provider based in Worcester, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821031097.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Max Rosen, MD MPH has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $66,000 received in 2024. These payments were reported across 395 transactions from 19 companies. The most common payment nature is "" ($1.1M).
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Worcester, MA
- Active Since 06/14/2006
- Last Updated 06/08/2021
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1821031097
Products in Payments
- OPDIVO (Biological) $376,670
- Avastin (Biological) $263,860
- KEYTRUDA (Biological) $214,020
- IMFINZI (Biological) $98,780
- TECENTRIQ (Biological) $70,600
- VENCLEXTA (Biological) $37,555
- ZYTIGA (Drug) $26,690
- Ibrutinib (Drug) $24,955
- ARZERRA (Drug) $19,250
- SUTENT (Drug) $15,230
- Venclexta (Drug) $13,375
- VENCLEXTA (Drug) $13,065
- M-7824 $6,420
- MRT-3020 $4,800
- MSB0011359C (Biological) $3,280
- CALQUENCE (Drug) $1,640
- Rituxan (Biological) $325.00
- Briefcase (Device) $106.00
- M7824 $20.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Worcester
Dr. Ajay Wakhloo, M.d, M.D
Diagnostic Radiology — Payments: $2.1M
Diagnostic Radiology $2.1M
Dr. Alexander Bankier, M.d, M.D
Diagnostic Radiology — Payments: $301,255
Diagnostic Radiology $301,255
Dr. Neil Resnick, M.d, M.D
Diagnostic Radiology — Payments: $242,910
Diagnostic Radiology $242,910
Hesham Malik, Md, MD
Diagnostic Radiology — Payments: $54,523
Diagnostic Radiology $54,523
Dr. Evan Watkins, M.d, M.D
Diagnostic Radiology — Payments: $17,711
Diagnostic Radiology $17,711
Mark Masciocchi, Md, MD
Diagnostic Radiology — Payments: $17,680
Diagnostic Radiology $17,680